BC
BDTX icon

Bridgefront Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Bridgefront Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,709
Closed -$191K – 343
2021
Q2 		$191K Buy
+15,709
New +$311K 0.07% 514

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bridgefront Capital's BDTX Position: Q3 2021 in Review

Bridgefront Capital sold out of Black Diamond Therapeutics (BDTX) in Q3 2021, closing a stake of 15,709 shares — an estimated $191K sold.

Bridgefront Capital first reported a position in BDTX in Q2 2021 and held it in 1 quarter. The position peaked at $191K in Q2 2021. 101 funds tracked by Wall St. Rank hold BDTX as of Q3 2021.

  • Bridgefront Capital reported no remaining Black Diamond Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 15,709 Black Diamond Therapeutics shares in Q3 2021, an estimated $191K.
  • Bridgefront Capital first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 1 quarter.
  • Bridgefront Capital's Black Diamond Therapeutics position peaked at $191K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.